Sodium arsenite induces hepatic stellate cells activation by m 6 A modification of TGF-β1 during liver fibrosis.

The compound known as Sodium arsenite (NaAsO2 ), which is a prevalent type of inorganic arsenic found in the environment, has been strongly associated with liver fibrosis (LF), a key characteristic of nonalcoholic fatty liver disease (NAFLD), which has been demonstrated in our previous study. Our previous research has shown that exposure to NaAsO2 triggers the activation of hepatic stellate cells (HSCs), a crucial event in the development of LF. However, the molecular mechanism is still unknown. N6-methyladenosine (m6 A) modification is the most crucial post-transcriptional modification in liver disease. Nevertheless, the precise function of m6 A alteration in triggering HSCs and initiating LF caused by NaAsO2 remains unknown. Here, we found that NaAsO2 induced LF and HSCs activation through TGF-β/Smad signaling, which could be reversed by TGF-β1 knockdown. Furthermore, NaAsO2 treatment enhanced the m6 A modification level both in vivo and in vitro. Significantly, NaAsO2 promoted the specific interaction of METTL14 and IGF2BP2 with TGF-β1 and enhanced the TGF-β1 mRNA stability. Notably, NaAsO2 -induced TGF-β/Smad pathway and HSC-t6 cells activation might be avoided by limiting METTL14/IGF2BP2-mediated m6 A modification. Our findings showed that the NaAsO2 -induced activation of HSCs and LF is made possible by the METTL14/IGF2BP2-mediated m6 A methylation of TGF-β1, which may open up new therapeutic options for LF brought on by environmental hazards.